Cervical Dystonia - FDA’s First-Cycle Review Of Dysport(R) To Be Completed By Year-End
Oct 3rd 2008Drug InformationBones
Ipsen (Paris:IPN) announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for DysportŪ (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
